Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Pancreatic Neoplasms 5Unspecified Adult Solid Tumor, Protocol Specific 1Resectable Pancreatic Carcinoma 1Resectable Pancreatic Cancer 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Breast Neoplasms 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1Advanced Pancreatic Cancer 1Adenocarcinoma of the Pancreas 1Adenocarcinoma 1

Interventions

Trastuzumab 351Paclitaxel 334Cyclophosphamide 315Docetaxel 292Capecitabine 181Doxorubicin 180Letrozole 165Tamoxifen 145Bevacizumab 124Fulvestrant 118Carboplatin 118exemestane 111Lapatinib 111Anastrozole 111Radiotherapy 105Epirubicin 104Gemcitabine 97palbociclib 83Exercise 78Vinorelbine 77Fluorouracil 77Surveys and Questionnaires 71pertuzumab 68Filgrastim 64Albumin-Bound Paclitaxel 64Magnetic Resonance Spectroscopy 56eribulin 55Everolimus 52Blood Specimen Collection 51Zoledronic Acid 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Breast Neoplasms × paricalcitol × Clear all
NCT00637897 2017-05-30

Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer

Wake Forest University Health Sciences

Phase 1 Completed
24 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡